Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/9617
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMcMahon, L Pen
dc.contributor.authorDawborn, J Ken
dc.date.accessioned2015-05-15T22:46:50Z
dc.date.available2015-05-15T22:46:50Z
dc.date.issued1992-05-16en
dc.identifier.citationAmerican Journal of Nephrology; 12(3): 162-9en
dc.identifier.govdoc1415377en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/9617en
dc.description.abstractThe quality of life of 12 hemodialysis (HD) patients was assessed in a prospective, blinded, cross-over fashion before treatment with recombinant human erythropoietin (r-HuEPO) and at two different levels of hemoglobin (Hb, 9 and 12 g/dl) by means of an interviewer-based questionnaire, the sickness impact profile (SIP). Patients were matched into two groups with no significant difference for age, weight, Hb (6.3 +/- 0.5, mean +/- SEM, group A, vs. 6.4 +/- 0.9 group B), length of hemodialysis or number of years of prior transplantation. SIP was assessed prior to treatment, after reaching the first target Hb (Hb 9 g/dl group A, 12 g/dl group B), after 4 months at that target Hb and after 4 months at the alternative target Hb for each group. For all patients, there was a highly significant improvement in quality of life as assessed by lower SIP scores between the initial and second assessments. This was evident for the physical (8.9 +/- 1.4 vs. 2.8 +/- 1.0; p less than 0.001) and psychosocial (14.9 +/- 3.9 vs. 4.4 +/- 1.1; p less than 0.01) dimensions. Total scores (16.3 +/- 2.4 vs. 5.7 +/- 0.9; p less than 0.001) showed similar changes, reflecting significant improvement in 10 of 12 possible categories between the first two assessments (p less than 0.05 to p less than 0.001). Improved scores were maintained but did not change appreciably after the 2nd assessment. There was no significant difference in any score (category, dimensional or total) obtained after 4 months at Hb 9 g/dl compared to those after the same period at Hb 12 g/dl.(ABSTRACT TRUNCATED AT 250 WORDS)en
dc.language.isoenen
dc.subject.otherAnemia.drug therapy.etiology.psychologyen
dc.subject.otherAttitude to Healthen
dc.subject.otherErythropoietin.therapeutic useen
dc.subject.otherHemoglobins.analysisen
dc.subject.otherHumansen
dc.subject.otherKidney Failure, Chronic.complications.therapyen
dc.subject.otherMiddle Ageden
dc.subject.otherProspective Studiesen
dc.subject.otherQuality of Lifeen
dc.subject.otherQuestionnairesen
dc.subject.otherRecombinant Proteins.therapeutic useen
dc.subject.otherRenal Dialysis.psychologyen
dc.titleSubjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin.en
dc.typeJournal Articleen
dc.identifier.journaltitleAmerican journal of nephrologyen
dc.identifier.affiliationDepartment of Medicine, Austin Hospital, Heidelberg, Victoria, Australiaen
dc.description.pages162-9en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/1415377en
dc.type.austinJournal Articleen
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

2
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.